Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Diagnostics and Genomics segment provides reagents, instruments, software, and consumables; arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment focused on production of synthesized oligonucleotides for use as active pharmaceutical ingredients.

Caris Life Sciences ® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).

Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (https://castletestinfo.com).
DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions on the risk of sentinel lymph node positivity and the intensity of follow-up, surveillance imaging, referral and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and sentinel lymph node status and is supported by consistent evidence in over 25 publications including two meta-analyses showing Level 1A evidence classification.
DecisionDx® DiffDx-Melanoma is a new gene expression profile test designed to reduce diagnostic uncertainty by providing a highly accurate and objective evaluation. DiffDx-Melanoma adds diagnostic clarity leading to a more confident diagnosis and a clearer treatment path for patients.
DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.
DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide.

Change Healthcare partners with providers, payers, and consumers to reduce costs, create efficiencies, and effectively manage complex workflows. Together we are accelerating the journey toward improved lives and healthier communities. We also help pathology practices and labs increase cash flow, patient revenue, and coding and compliance with our billing, collection, and revenue cycle management services.

Cleveland Clinic Laboratories is dedicated to providing high-quality, clinically impactful pathology and laboratory diagnostic services combined with readily available consultation from experienced pathologists and laboratory scientists. Our laboratories offer excellence in coagulation, flow cytometry, hematopathology, molecular testing and cytogenomics, and microbiology as well as subspecialty services in anatomic pathology. This approach ensures that every specimen submitted will be evaluated by a pathologist with a high level of diagnostic expertise in that specific field of pathology.

CSI Laboratories is a leading cancer testing and diagnostics laboratory trusted by pathologists, oncologists, and community hospitals throughout the U.S. For more than 22 years, we've been at the forefront of advanced testing methods, using a collaborative approach to manage testing with speed, precision and care, and delivering testing that is medically necessary and clinicaly significant. CSI provides a full complement of cancer testing, including Flow, Cytogenics, FISH, IHC, and Molecular services. Our national cancer testing laboaratory has one mission: Keeping our clients and their patients at the forefront of everything we do.

ELITechGroup has been in operation for over 50 years and distributes to over 100 countries. Proud to be the World Leader in Aerospray staining technology and Cytocentrifugation, offering the world's most reliable solutions in performance and reliability. ELITechGroup is confident that this automated technology will elevate the performance of any laboratory and facilitate superior results.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases.

Interpace Diagnostics is a leading provider of molecular testing for thyroid and pancreatic cancer.  The Company offers ThyGeNEXT® and ThyraMIR®, a unique approach that combines a mutation panel with a microRNA classifier for Thyroid cancer.  These tests, utilizing the Markers That Matter™, have been fully validated with a demonstrated NPV of 97% and PPV of 75%. Also available are PancraGEN® and PanDNA®, which help in stratifying cancer risk of pancreatic cysts or biliary strictures. By integrating a proprietary combination of tumor suppressor genes and loss of heterozygosity with imaging, chemistries, and other first line testing, a risk classification is determined to help inform the best course of action, from surgery to active surveillance. 

Labcorp Oncology believes in harnessing science to improve health and the lives of people with cancer. And so we work day and night, around the world, to support the delivery of more treatment options - whether you're a healthcare provider, pharmaceutical company, hospital, medical researcher or patient.

MagMutual is a provider of Medical Malpractice insurance and practice solutions, including patient safety services to over 25,000 physicians and hospitals.

MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.

NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore.

PIMS Inc. was incorporated in 1998 and has evolved into a full-service Medical Billing and Practice Management Services company. PIMS provides comprehensive billing and consulting services for providers of all sizes. In addition, PIMS offers an innovative and robust laboratory information system designed specifically for the anatomic pathology practice in mind.

Roche Diagnostics is one of the world’s leaders in medical diagnostic instrument and reagent systems providing leading-edge automation for use in the diagnosis of cancer and infectious disease.

We are building awareness around Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an aggressive and deadly blood cancer that often presents with skin lesions.  Historically, the average time to diagnosis is 6 months, and following diagnosis the median overall survival is approximately 8 to 14 months.  An early and accurate diagnosis is critical in improving patient outcomes, which is why it is important to include CD123, CD4, and CD56 in your hematologic diagnostic panel.  THINK CD123456! 

Vachette is a pathology laboratory consulting firm. We specialize in revenue cycle auditing, reworking revenue cycle processes, and negotiating managed care contracts. Our three-tiered process of revenue strategy, revenue management, and revenue insurance helps our clients find millions of dollars in lost revenue each year. Imagine having a professional team assess your revenue cycle process. How would your billing team perform? We audit over $1 billion in medical billings annually. Isn't it time to see how you score?